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THE RIGHT TO CHOOSE AN UNPROVEN
METHOD OF TREATMENT
I. INTRODUCTION
In the past decade there has been a growing controversy over the
right of medical patients to choose treatments of unproven efficacy. A
prominent focal point of the controversy was the use of laetrile' for the
treatment of cancer. Laetrile has not been approved as a new drug by
the Food and Drug Administration (FDA) and therefore cannot be
sold or distributed in interstate commerce.2 In addition, various state
regulations have prohibited its use. For example, the California Health
and Safety Code prohibits the use, sale, prescription, or distribution of
laetrile within the state.' Thus deprived of the use of laetrile, cancer
patients have sought judicial pronouncement that these statutes violate
1. Laetrile, also referred to as amygdalin, aprikem, Bee 17, Vitamin B17, and nitrilo-
side, is a food extract obtained from the pits of edible fruits such as peaches and apricots.
Advocates of laetrile believe that cancer is the result of a deficiency that can be cured by
Vitamin B17 found in food extracts. "The theory was that cancer cells were rich in the
enzyme betaglucuronidase which was supposed to cleave Laetrile eventually to cyanide,
thereupon killing the cancer cells, but normal cells survived since they were low in that
enzyme." The normal cells contain another enzyme known as rhodanase that inactivates the
cyanide, making it harmless. Thus the cyanide seeks out cancer cells, low in rhodanase, and
destroys them. Price & Price, Laetrile-An Overview, 48 J. SCH. HEALTH 409, 409-10 (1978)
[hereinafter cited as Overview]; Stang, Laetrile-Freedom of Choice in Cancer Therapy, 2:4
CANCER CONT. J. 9, 10-11 (1974) [hereinafter cited as Freedom of Choice].
2. An application pursuant to 21 U.S.C. § 355 (1976) must be filed and approved
before a drug can be transported in interstate commerce. Since the FDA has not granted
this approval to the manufacturers of laetrile, laetrile is barred from interstate commerce.
The FDA, however, has now approved human testing with laetrile. FD,4 Indicates It Will
OKLaetrile Tests on Humans, L.A. Times, Jan. 3, 1980, Part 1, at 1, col. 1.
The FDA's requirements for approval of new drugs has engendered debate about
whether laetrile qualifies under one of the exemption clauses. See Note, Freedom of Choice
in Medical Treatment- Reconsidering the Efficacy Requirement of the FDA, 9 Loy. CHI. L.J.
205 (1977); Note, Picking Your Poison.- The Drug Efficacy Requirement and the Right of Pri-
vacy, 25 U.C.L.A. L. REv. 577 (1978); Note, Laetriie: Statutory and ConstitutionalLimitation
on the Regulation of Ineffective Drugs, 127 U. PA. L. Rnv. 233 (1978).
3. CAL. HEALTH & SAFETY CODE § 1707.1 (West Supp. 1979) provides:
The sale, offering for sale,. . . prescribing or administering of any drug. . . to be
used in the diagnosis, treatment, alleviation or cure of cancer is unlawful and pro-
hibited unless (1) an application.. . has been approved under Section 505 of the
Federal Food, Drug, and Cosmetic Act, or (2) there has been approved an applica-
tion filed with the board. ...
Since no application has been approved, the sale or distribution of laetrile is prohibited in
California. Section 505 of the Federal Food, Drug, and Cosmetic Act has been repealed and
the California section should be read to refer to § 355 of the Act instead.
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their constitutional rights. To date, these efforts have been unsuccess-
ful.
In People v. Privitera,4 the California Supreme Court decided that
cancer patients have no right under either the Federal or California
Constitution to use laetrile.5 This comment proposes that terminally ill
patients should have a protected right under both the Federal and Cali-
fornia Constitutions to use drugs of unproven efficacy, including lae-
trile.6 There are, however, factors that may justify governmental
restrictions upon the use of unproven remedies by patients who are not
terminally ill.
This comment first examines the constitutional right of privacy
and its application to medical patients and then examines state interests
in limiting the use of treatments or drugs of unproven efficacy, particu-
larly laetrile. Finally, a proposed regulation is suggested that attempts
to meet state interests without impinging unduly upon the interests of
terminally ill patients.
II. RIGHT OF PRIVACY
The Supreme Court has granted special protection to those indi-
vidual rights that are classified as "fundamental. ' ' 7 If a state law inter-
*res with a fundamental right, a strict scrutiny test" is invoked that
requires a showing by the state that the law is necessary to protect a
4. 23 Cal. 3d 697, 591 P.2d 919, 153 Cal. Rptr. 431 (1979). A licensed physician who
prescribed laetrile for the treatment of cancer was charged, as were two other defendants,
with illegally importing and supplying laetrile.
5. The court held that the "right to obtain drugs of unproven efficacy is not encom-
passed by the right of privacy embodied in either the federal or state Constitutions." Id at
702, 591 P.2d at 921, 153 Cal. Rptr. at 433.
6. The U.S. Supreme Court has specifically held that there is no exemption from the
FDA's regulations over the interstate transportation of laetrile for its use by terminally ill
persons. United States v. Rutherford, 442 U.S. 544, 555 (1979).
7. "Fundamental rights" are also referred to as rights that are "implicit in the concept
of ordered liberty." Palko v. Connecticut, 302 U.S. 319, 325 (1937). Rights deemed funda-
mental include the right of privacy, the right to interstate travel, the right to equal voting
opportunity, the right to equal litigation opportunity, and the right against invidious racial
discrimination. L. TRIBE, AMERICAN CONSYITUTIONAL LAW 1003-11 (1978).
8. There are two major standards of review of state regulations: the strict scrutiny test
and the rational basis test. When fundamental rights are effected by the particular regula-
tion, then the strict scrutiny test is invoked, which provides that the "regulation limiting
these rights may be justified only by a 'compelling state interest,' . . . [and] the legislative
enactments must be narrowly drawn to express only the legitimate state interests at stake."
Roe v. Wade, 410 U.S. 113, 155 (1973). When the individual right involved is not funda-
mental, the regulation usually is reviewed by the lower rational basis standard under which
the particular regulation will be upheld if there is any rational relationship between the
regulation and a legitimate state interest.
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compelling state interest. Unless the state sustains its burden of proof
in establishing a compelling interest, the statute should be held uncon-
stitutional.
The Court has found the right of privacy to be fundamental and
thereby entitled to this special protection.9 The scope of activities pro-
tected by the privacy right has developed on a case-by-case basis. It is
essential, therefore, to examine those activities already held to be pro-
tected in order to determine whether the right should be extended to
include the right of an individual to choose an unproven medical treat-
ment.
A. Federal Constitution
1. History of the Privacy Right
The right of privacy was first acknowledged as fundamental by the
Supreme Court in Griswold v. Connecticut."° Invoking the strict scru-
tiny standard, the Court found a Connecticut statute, which prohibited
the use of contraceptives, unconstitutional on the basis that it impinged
upon the "privacy surrounding the marriage relationship.""
In Eisenstadt v. Baird,2 the Court shifted the focus of the privacy
right from the protection of a relationship to the protection of the rights
of individuals. The Court struck down a Massachusetts statute prohib-
iting the disbursement of contraceptives to unmarried individuals, rea-
soning that the "right of privacy . . . is the right of the individual,
married or single, to be free from unwarranted governmental intrusion
into matters so fundamentally affecting a person as the decision
whether to bear or beget a child."' 3
9. Griswold v. Connecticut, 381 U.S. 479, 485 (1965). Although the right of privacy is
not expressly protected by the Bill of Rights, the Supreme Court found it to be within the
penumbral rights of the first eight amendments. Id "Justice Douglas' argument [in the
majority opinion] seems to go something like this: since the Constitution, in various 'specif-
ics' of the Bill of Rights and in their penumbra, protects rights which partake of privacy, it
protects other aspects of privacy as well, indeed it recognizes a general, complete right of
privacy. And since the right emanates from specific fundamental rights, it too is 'fundamen-
tal'.... ." Henkin, Privacy andAutonomy, 74 COLUM. L. Rlv. 1410, 1421 (1974). In con-
curring opinions in Griswold, Justice Goldberg anchored the privacy right to the ninth
amendment, 381 U.S. at 487 (Goldberg, J., concurring), while Justice Harlan anchored it to
the fourteenth amendment, id. at 500 (Harlan, J., concurring).
10. 381 U.S. 479 (1965).
11. Id at 485-86.
12. 405 U.S. 438 (1972).
13. Id at 453. The Court held that the state statute violated "the rights of single persons
under the Equal Protection Clause of the Fourteenth Amendment." Id at 443. "If under
Griswold the distribution of contraceptives to married persons cannot be prohibited, a ban
on distribution to unmarried persons would be equally impermissible." Id at 453.
1979]
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Still within the context of procreation, the Court in Roe v. Wade,14
further developed the privacy right to include a woman's decision to
terminate her pregnancy.' 5 The Court justified the expansion of the
right on the basis of the significant impact on the lifestyle of the woman
if she were denied the choice to have an abortion.' 6 However, the
Court stated that its expansion of the right did not create an "unlimited
right to do with one's body as one pleases."' 7 It recognized that there
may be state interests that justify regulation of some aspects of activi-
ties protected by the right.'8
The most comprehensive definition of the privacy right appears in
dicta in Whalen v. Roe.'9 The Court stated that there are two types of
interests embraced within the right to "privacy": an "individual inter-
est in avoiding disclosure of personal matters, and . . . the interest in
independence in making certain kinds of important decisions."20 Thus,
the Court has expanded the privacy right from protection of a particu-
lar relationship or activity to protection of the individual's right to
make important decisions.
14. 410 U.S. 113 (1973).
15. "This right of privacy . . . is broad enough to encompass a woman's decision
whether or not to terminate her pregnancy." Id at 153.
16. The Court mentioned specific detrimental effects on the pregnant woman such as the
medical harm in early pregnancy, the distressful life of maternity, psychological harm, taxa-
tion of the mother's physical health by caring for a child, and the possible distress in raising
an unwanted child in a home psychologically unable to care for it. Id
17. Id at 154.
18. Id at 177-78. The Court decided that there are two compelling state interests justi-
fying some regulation of the right to have an abortion: protection of the health of the
mother and protection of potential life. Using an analysis that is analogous to that provided
herein for resolution of the laetrile dispute, see notes 102-105 infra, the Court allowed in-
creasing state regulation as the pregnancy progressed:
(a) For the stage prior to approximately the end of the first trimester, the abortion
decision and its effectuation must be left to the medical judgment of the pregnant
woman's attending physician.
(b) For the stage subsequent to approximately the end of the first trimester, the
State, in promoting its interest in the health of the mother, may, if it chooses, regu-
late the abortion procedure in ways that are reasonably related to maternal health.
(c) For the stage subsequent to viability, the State in promoting its interest in the
potentiality of human life may, if it chooses, regulate, and even proscribe, abortion
except where it is necessary, in appropriate medical judgment, for the preservation
of the life or health of the mother.
Id at 164-65.
19. 429 U.S. 589 (1977).
20. Id at 599-600. The Court upheld against challenge a New York statute requiring a
computerized record of certain prescription drugs, concluding that the impact of the records
on the reputation and independence of patients was not sufficient to constitute an invasion
of any right or liberty protected by the Constitution. Id at 603.
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2. Right To Refuse Medical Treatment
The right to decline medical treatment originally arose in the con-
text of religious objections to blood transfusions and operations.2'
Later, cases extended the right to refuse medical treatment on bases
other than first amendment protection of religion, including the basis of
the right to privacy.22 The right to. refuse medical treatment is not,
however, absolute. Generally, courts have considered two factors when
determining whether the right should be recognized in a particular
case: whether the patient has minor children who would become wards
of the state23 and whether public health would be endangered if the
patient refused treatment.24 When neither of these dangers exist, the
courts have typically recognized the right.
In re President and Directors of Georgetown College, Inc. 26 is a
prominent example of a court's refusal to allow a patient with a minor
child to decline medical treatment. Because the patient was the mother
of a seven-month old child, the court refused to allow her to decline
blood transfusions despite her religious objections.27 In Jacobson v.
Massachusetts,28 the Supreme Court acknowledged "the inherent right
of every freeman to care for his own body and health, ' 29 but it did not
permit Jacobson to refuse vaccination for smallpox because of the dan-
21. The cases in this area primarily have concerned the right of a Jehovah's Witness to
refuse blood transfusions. See Cantor, A Patient's Decision To Decline Life-Saving Medical
Treatment: Bodily lntegri y Versus the Preservation ofLfe, 26 RuTGERS L. REv. 228, 230-36
(1973).
22. See text accompanying notes 35-38 infra.
23. See, e.g., In re President and Directors of Georgetown College, Inc., 331 F.2d 1000
(D.C. Cir.), cert. denied, 377 U.S. 978 (1964); Raleigh Fitkin-Paul Morgan Mem. Hosp. v.
Anderson, 42 N.J. 421,201 A.2d 537, cert. denied, 377 U.S. 985 (1964) (legitimate state inter-
est in the protection of an unborn child carried by the mother).
24. Jacobson v. Massachusetts, 197 U.S. 11 (1904) (the state's interest in preventing
epidemics overrides the individual's right to refuse vaccination).
25. See In re Melideo, 88 Misc. 2d 974, 390 N.Y.S.2d 523 (1976) (a competent patient
who is not pregnant and has no children has the right to refuse blood transfusions); Aste v.
Brooks, 32 11. 2d 361, 373, 205 N.E.2d 435, 440 (1965) (although incompetent at the time of
the court order, patient had made known her religious beliefs to her physician for the past
two years and had no minor children). Under current analysis, these two factors would be
referred to as compelling state interests.
26. 331 F.2d 1000 (D.C. Cir.), cert. denied, 377 U.S. 978 (1964).
27. Id at 1008. The court reasoned that the mother of a seven-month old child has a
responsibility to take care of the child. "Thus, the people have an interest in preserving the
life of this mother." Id The judge considered four factors: (1) the patient had an infant
child, (2) she did not want to die, (3) "a life hung in the balance," and (4) the patient was so
physically weak that she could not make a rational decision for herself. Id at 1008-09. See
also United States v. George, 239 F. Supp. 752 (D. Conn. 1965).
28. 197 U.S. 11 (1905).
29. Id at 26.
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ger to the public from a possible epidemic.30 The Court thus acknowl-
edged that the protection of public health can outweigh an individual's
right to decline treatment.
A competent adult, however, who does not have a dependent child
and does not pose a danger to public health, may refuse medical care
even if so doing is substantially certain to result in his death.3' In In re
Maida Yetter,32 a patient wished to refuse surgery and the court con-
cluded that the "right of privacy includes a right to die with which the
State should not interfere where there are no minor or unborn children
and no clear and present danger to public health, welfare or morals. 33
In the recent controversial case of In re Quinlan,34 the New Jersey
Supreme Court presumed that the constitutional right of privacy is
"broad enough to encompass a patient's decision to decline medical
treatment. ' 35 The court concluded that the state's interest, the preser-
vation of human life, and the physician's right to use his best judgment
in administering treatment,36 are overcome by the individual's rights
when there is no chance of his recovering. 37 The court reasoned that
the "State's interest weakens and the individual's right to privacy grows
as the degree of bodily invasion increases and the prognosis dims."
'38
The right recognized in Quinlan is protected in California by the
Natural Death Act.39 According to the Act, "[a]ny adult may execute a
directive directing the withholding or withdrawal of life sustaining pro-
30. Id at 37.
31. The New York Supreme Court held that an adult patient has the right to refuse
blood transfusions despite medical opinion that "the patient's decision not to accept blood is
just about the taking of his own life." Erickson v. Dilgard, 44 Misc. 2d 27, 28, 252 N.Y.S.2d
705, 706 (1962) (special term).
32. 62 Pa. D.&C.2d 619 (1973).
33. Id at 623.
34. 70 N.J. 10, 355 A.2d 647, cert. deniedsub noma. Garger v. New Jersey, 429 U.S. 922
(1976). Miss Quinlan, a twenty-two year old woman who had become comatose, was in a
vegetative state, dependent upon life-support systems. Her father sought a court order to
appoint him as guardian with the express power to terminate her life-sustaining treatment.
The Quinlan case generated a number of commentaries. See, e.g., Cantor, Quinlan, Privacy
and the Handling o/Incompetent Dying Patients, 30 RUTGERS L. REV. 243 (1977); Collester,
Death, Dying, and the Law: .4 Prosecutorial View of the Quinlan Case, 30 RUTGERS L. RaV.
304 (1977); Comment, In re Quinlan: One Court's 4nswer to the Problem of Death with
Dignily, 34 WASH. & LEE L. REv. 285 (1977).
35. 70 N.J. at 40, 355 A.2d at 663.
36. Id
37. Id at 41, 355 A.2d at 664.
38. Id Similar to Roe, the New Jersey court recognized a change in the state's interests
as the health of the patient changes. See note 18 supra.
39. CAL. HEALTH & SAFETY CODE §§ 7185-7195 (West Supp. 1979).
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cedures [while] in a terminal condition. ' 40 The legislature recognized
that: (1) "adult persons have the fundamental right to control the deci-
sions relating to the rendering of their own medical care"; and (2) "pro-
longation of life for persons with a terminal condition may cause loss of
patient dignity and unnecessary pain and suffering while providing
nothing medically necessary."' 4 1 This enactment reflects the conclusion
in Quinlan that "[u]ltimately there comes a point at which the individ-
ual's rights overcome the State interest. '42 If the courts and legislature
recognize a right to refuse treatment when in some instances such treat-
ment would save life, then they likewise should recognize a patient's
right to choose an unproven treatment that may preserve his life.
3. The Right To Choose an Unproven Medical Treatment
In order to give any significant protection to the right to choose an
unproven treatment, the right must be characterized as fundamental,
i*e., within the purview of the privacy right.43 In People v. Privitera,4
4
the California Supreme Court held that an individual's decision re-
garding medical treatment is not protected by the right of privacy, rea-
soning that the United States Supreme Court limited the right to
"important decisions" involving" 'matters relating to marriage, procre-
ation, contraception, family relationships, and child rearing and educa-
tion.' ,41 The Court in Whalen v. Roe, 46 however, suggested that the
decision to acquire and use medication is an important decision that
may fall within the protection of the right of privacy.47 In addition,
when determining whether a right is fundamental, the Court considers
the impact of the decision on the lifestyle of the individual. The deci-
40. Id. § 7188. The Act applies only to a patient suffering from a terminal condition,
which the Act defines as "an incurable condition caused by injury, disease, or illness, which,
regardless of the application of life-sustaining procedures, would, within reasonable medical
judgment, produce death, and where the application of life-sustaining procedures serve only
to postpone the moment of death of the patient." Id § 7187(f). The Act defines "life-sus-
taining procedure" as "any medical procedure or intervention which utilizes mechanical or
other artificial means to sustain, restore, or supplant a vital function . . . .[It] shall not
include the administration of medication or the performance of any medical procedure
deemed necessary to alleviate pain." Id § 7187(c).
41. Id § 7186.
42. 70 N.J. at 41, 355 A.2d at 664.
43. If the right is deemed not to be fundamental then the standard of review for the
regulation usually will be the lower rational basis test. See note 8 supra.
44. 23 Cal. 3d 697, 591 P.2d 919, 153 Cal. Rptr. 431 (1979).
45. Id at 702, 591 P.2d at 922, 153 Cal. Rptr. at 434 (quoting Whalen v. Roe, 429 U.S.
589, 599-600 (1977)).
46. 429 U.S. 589 (1977).
47. Id at 509-600.
1979]
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sion of a patient to use a treatment of unknown efficacy can have a
significant impact on his lifestyle, suggesting that such a decision
should be included within the privacy right.
Griswold v. Connecticut48 and Roe v. Wade49 are leading examples
of the Court's emphasis on the degree of intrusion into the individual's
lifestyle when determining the fundamental nature of the right in-
volved. In Griswold, the state law forbidding the use of contraceptives
had a "maximum destructive impact"50 upon the marital relationship.
The enforcement of the state regulation would have required the "po-
lice to search the sacred precincts of marital bedrooms for telltale signs
of the use of contraceptives."5 This severe governmental invasion into
the lives of married couples led the Court to conclude that a couple's
right to use contraceptives is fundamental." The effect of the state reg-
ulation on the individual's lifestyle played an important role when the
Court decided in Wade that the right to have an abortion is fundamen-
tal. 3 The Court mentioned specific detrimental effects on the pregnant
woman, such as medical harm in early pregnancy, taxation of the
mother's physical health by caring for a child, and the possible distress
in raising an unwanted child. 4
The severity of the impact resulting from a state's prohibition on
the use of unproven remedies varies with the severity of the illness. A
prohibition on using unproven remedies usually will not have a partic-
ularly severe impact on non-terminal patients who retain a chance of
recovery from orthodox treatments.55 To deny a terminal patient his
last chance of recovery, however, results in a "maximum destructive
impact"56 and the right to choose a treatment of unproven efficacy
48. 381 U.S. 479 (1965).
49. 410 U.S. 113 (1973).
50. 381 U.S. at 485.
51. Id
52. Id
53. 410 U.S. 113 (1973). See also Planned Parenthood v. Danforth, 428 U.S. 52, 79
(1976) (state law prohibiting a particular technique of abortion held invalid because of its
inhibiting effect upon the exercise of the individual's abortion right). But see Fitzgerald v.
Porter Mem. Hosp., 523 F.2d 716 (7th Cir. 1975), cert. denied, 425 U.S. 916 (1976) (the
decision regarding the method of childbirth held to be of less importance to married couples
than the question of whether the child shall be born).
54. 410 U.S. at 153.
55. Since there exist remedies proven to be effective, the deprivation of the unproven
remedy does not result in a severe enough impact. See text accompanying notes 87-96 infra.
56. Griswold v. Connecticut, 381 U.S. at 485. A terminal patient, for whom there exists
no proven effective treatments, experiences a severe impact when deprived of an unproven
remedy and is placed in the same position as Karen Quinlan, "to endure the unendurable."
In re Quinlan, 70 N.J. 10, 39, 355 A.2d 647, 663, cert. deniedsub norm. Garger v. New Jersey,
429 U.S. 922 (1976).
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should therefore be given protection. Chief Justice Bird, in her dissent
in Privitera, stated that "[fMrom the terminal patient's viewpoint a new
depth of inhumanity is reached by a broad sweep of. . . [this Califor-
nia] law."57
There is no basis in logic for refusing to recognize the right to
choose an unproven remedy while at the same time protecting a pa-
tient's right to refuse proven remedies. In Erickson v. Dilgard,53 the
court recognized the right to refuse treatment on the basis that it is the
patient who is the subject of the decision and, therefore, he should have
the final say. 9 It is ironic that the courts protect the right to refuse
medical treatment when in some instances such treatment would save
life but refuse to protect the right of a terminally ill patient to accept
treatment of unknown efficacy as a last resort to preserve life. The de-
cision to live should be considered more important than the decision to
die; for courts to protect the latter but not the former is more than in-
consistent, it is absurd.
Thus, recognizing a right of terminally ill patients to choose an
unproven remedy would be a logical progression from recognizing the
right to refuse treatment, as well as an appropriate expansion of the
privacy doctrine. Once the right is recognized as fundamental, the state
must prove a compelling interest to justify any infringement upon it.
B. State Constitution
While states are required to protect rights guaranteed by the Fed-
eral Constitution, they may also grant greater protection. If the right to
choose an unproven treatment is within the purview of the federal right
of privacy,1° then state laws must not impinge upon the right in the
absence of a compelling state interest. Even if this right is not protected
under the Federal Constitution, the state may create an independent
right of privacy and give to it a broader scope of protection than that
already provided by the federal privacy right.
In California, the state constitution was amended by the voters to
expressly protect the right of privacy.61 It now reads: "All people are
by nature free and independent and have inalienable rights. Among
57. 23 Cal. 3d at 740, 591 P.2d at 946, 153 Cal. Rptr. at 458 (Bird, C.J., dissenting).
58. 44 Misc. 2d 27, 252 N.Y.S.2d 705 (Sup. Ct. 1962).
59. Id. at 28, 252 N.Y.S.2d at 706. Consistent with Erickson, Professor Gerety stated
that "if we don't control our bodies, what do we control? - and who are we? The body is
the necessary condition of both identity and autonomy." Gerety, Redefning Privacy, 12
HARV. C.R.-C.L.L. REv. 233, 266 n.l 19 (1977).
60. See text accompanying notes 47-54 supra.
61. CAL. CONST. art. 1, § 1.
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these are enjoying and defending life and liberty, acquiring, possessing,
and protecting property, and pursuing and obtaining safety, happiness,
andprivacy."62 Dispute, however, has arisen over the scope of the pro-
tection created by this language. In Privitera, the California Supreme
Court stated that the purpose of the provision is to protect against sur-
veillance and data collecting, basing its conclusion on a prior case in-
volving these activities, White v. Davis,63 and the amendment's election
brochure. ' An examination, however, of both the White opinion and
the election brochure demonstrates that the right of privacy created by
the California Constitution has a much broader scope.
While the California Supreme Court in White found that "the
moving force behind the new constitutional provision was a more fo-
cussed privacy concern," 65 it stated that "the full contours of the new
constitutional provision have as yet not even tentatively been sketch-
ed,"66 and it intimated "no opinion as to the resolution of the ultimate
constitutional question. ' 67 Therefore, the White court merely ad-
dressed one facet of the new privacy right, data gathering and surveil-
lance, but did not intend its conclusion to be dispositive of the full
scope of the provision.
A recognized method of construing a constitutional amendment
approved by a vote of the people is to look to the statements of the
election brochure.6  The election brochure for this constitutional
amendment provides:
"The right ofprivacy is the right to be left alone. It is a funda-
mental and compelling interest. It protects our homes, our
families, our thoughts, our emotions, our expressions, our per-
sonalities, our freedom of communion, and our freedom to
associate with the people we choose.
The right of privacy is an important American heritage
and essential to the fundamental rights guaranteed by the
First, Third, Fourth, Fifth and Ninth Amendments to the
U.S. Constitution. This right should be abridged only when
62. Id (emphasis added).
63. 13 Cal. 3d 757, 533 P.2d 222, 120 Cal. Rptr. 94 (1975).
64. 23 Cal. 3d at 709-10, 591 P.2d at 926, 153 Cal. Rptr. at 438. See text accompanying
note 69 infra for quotation from brochure.
65. 13 Cal. 3d at 774, 533 P.2d at 233, 120 Cal. Rptr. at 106.
66. Id at 773, 533 P.2d at 233, 120 Cal. Rptr. at 105.
67. Id at 776, 533 P.2d at 235, 120 Cal. Rptr. at 107.
68. Id. at 775 n.ll, 533 P.2d at 234 n.ll, 120 Cal. Rptr. at 106 n.ll.
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there is compelling public need."69
Based upon the express language of the brochure, the new constitu-
tional provision was intended to shield against more than surveillance
and data collecting; it was meant to protect "'our thoughts, our emo-
tions, our expressions, [and] our personalities.' "70 As stated in White,
this encompasses an "enormously broad and diverse field of personal
action and belief."' 7 Therefore, contrary to the holding in Privitera, the
California right of privacy at its inception seems to have been intended
to provide similar but broader protection than does the federal privacy
right and could be reasonably interpreted as including the right to
choose treatments of unproven efficacy.
III. STATE INTERESTS
A statute that impinges upon a fundamental right is constitutional
only if it is narrowly drawn to serve a compelling state interest.72 The
principal state interest served by regulating unproven drugs is the pro-
tection of the health and welfare of the state's inhabitants.73 Using a
rational basis standard, the court in Privitera concluded that the state's
interest in public health bears a reasonable relationship to the statute
that prohibits the use of laetrile.74 An examination of this interest,
however, demonstrates that it is not sufficiently compelling to warrant
an absolute prohibition of the drug.
A. Protection of Health and Wefare
Roe v. Wade75 is a leading example of the analysis the Court uses
to determine the sufficiency of a state's interest in the protection of a
person's health when a statute is challenged as impinging upon a fun-
damental right to choose a medical procedure. In Wade, the Court
held that no compelling state interest exists until after the end of the
first trimester of pregnancy, at which point the risk of mortality from
the abortion procedure is higher than at normal childbirth.76 The
69. People v. Privitera 23 Cal. 3d at 728, 591 P.2d at 938, 153 Cal. Rptr. 450 (Bird, C.J.,
dissenting) (quoting the election brochure).
70. Id
71. White v. Davis, 13 Cal. 3d at 774, 533 P.2d at 233, 120 Cal. Rptr. at 105 (discussing
the election brochure).
72. See notes 7 & 8 supra and accompanying text.
73. Roe v. Wade, 410 U.S. 113, 154 (1973).
74. 23 Cal. 3d at 708-09, 591 P.2d at 925-26, 153 Cal. Rptr. at 438.
75. 410 U.S. 113 (1973).
76. Id at 149.
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Court basically used a risk/benefit analysis. 7 The conclusion seems to
be that there is no compelling state interest in the protection of an indi-
vidual's health until it can be shown that the patient's health is benefit-
ted more by the state's alternative than by the treatment chosen by the
patient. Applying this approach to cancer patients, whether or not
there exists a compelling state interest can be determined by analyzing
the risk/benefit ratio of the orthodox treatments and treatments of un-
proven efficacy.
Orthodox treatments are currently successful fifty percent of the
time in curing fifteen of the one hundred ascertained types of cancer for
five years.78 This amounts to an overall success rate of 7.5%.79 Because
there is no indication of more successful cures in the near future, the
plight of the cancer patient appears dim."
Currently, chemotherapy, radiation, and surgery, the three pri-
mary methods of treatment,8I have a low rate of success and present a
high risk of harm to the patient. One commentator admits that "toxic
chemotherapy is much more a guess than a therapeutic certainty in the
majority of cancer cases." 2 Chemotherapy is known to eradicate only
two types of cancer.83 Furthermore, chemotherapy results in various
side effects and, in some instances, death.84 Some of the milder effects
include nausea, vomiting, diarrhea, infections, hemorrhage, cramps, di-
minished appetite, and loss of hair.85 More seriously, one study indi-
cates that there is a death rate of ten percent from chemotherapy. 86
77. For a detailed analysis of the risks and benefits inherent in drug regulation, see W.
Ross, THE LIFE/DEATH RATIO-BENEFITS AND RISKS IN MODERN MEDICINES (1977) [her-
einafer cited as LIFE/DEATH].
78. Freedom of Choice, supra note 1, at 10. Each year cancer is the cause of 350,000
deaths. It is estimated that 50 million people will contract the disease in the future. Id
79. Id
80. James Watson, Nobel Prize winning biologist, stated, "While ... [many people are]
being told about cancer cures, the cure rate has improved only about one per cent." Cancer
Program a Sham, Nobel Laureate Asserts, 4:5 CANCER CONT. J. 37, 37 (1976).
81. Klaassen, Present Status of Cancer Chemotherapy, 117 CANCER MED. Assoc. J.
1117, 1117 (1977) [hereinafter cited as Chemotherapy].
82. Sokoloff, Can Toxic Chemotheraphy Cure Cancer?, 41 GROWTH 237, 237 (1977).
83. Burkitt's tumor and placental choriocarcinoma are the only types of cancer that
chemotherapy is able to eradicate. Id at 238. See also The Myth of Proven Remedies-4
Very Grim Picture," 1:1 CANCER CONT. J. 6, 7 (1973) [hereinafter cited as Grim Picture].
84. Serious side effects occur with chemotherapy because of the drug's imperfect selec-
tive destruction, which causes damage to normal tissues. "An evaluation of the worth of any
chemotherapeutic regimen must be analyzed as cost versus benefit, in which benefit is tumor
regression and the cost is host toxicity." Friedman, Serious Toxicities Associated with Chem-
otherapy, 5 SEMINARS IN ONCOLOGY 193, 193 (1978).
85. Freedom of Choice, supra note 1, at 10; Chemotherapy, supra note 81, at 1117.
86. Freedom of Choice, supra note I, at 10.
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Treatment by use of radiation therapy does not paint a brighter
picture. Although it has been in extensive use for decades, "it is still
not possible to prove an unequivocal clinical benefit. '87 Radiation
therapy proves effective in curing or controlling a localized tumor but
has failed, with only rare exception, to control or cure a metastatic type
of cancer.8 The evaluation of clinical evidence by one commentator is
that "no increase in survival has been achieved by the addition of irra-
diation."8 9
Similarly, surgery has not proven very effective in halting cancer.
As with radiation therapy, surgery is effective in the cure and control of
a localized tumor, but has proved useless, with rare exceptions, in the
treatment of a metastatic cancer.90 Yet the mortality risk of surgery has
been estimated by some at 20,000 to 30,000 deaths in nearly 2,000,000
procedures per year.91 Thus, not only do the three orthodox methods
of treatment have low rates of success, but each involves serious risks to
the patient's health.
The benefits and risks of laetrile, as of all unproven drugs, are still
in dispute. Many opponents of the drug claim that it is toxic, causing
cyanide poisoning.92 A few fatalities allegedly caused by excessive con-
sumption of laetrile have been reported;93 however, the National Can-
cer Institute (NCI), at the request of the FDA, conducted toxicity tests
on laetrile and concluded that there are no ill effects from its supervised
87. Grim Picture, supra note 83, at 6.
88. Chemotherapy, supra note 81, at 1117.
89. Grim Picture, supra note 83, at 7.
90. Chemotherapy, supra note 81, at 1117.
91. LIFE/DEATH, supra note 79, at 7. In 1975, it was estimated that 250,000 Americans
died during or immediately after surgery. Incompetent Surgery Is Found Not Isolated, N.Y.
Times, Jan. 28, 1976, § 1, at 1, col. 6. The degree of risk (the percentage of fatalities) permit-
ted for surgery, which is merely life-improving and not life-saving, is I to 1.5%. The risk of
fatalities for a life-saving drug, however, must be .0005 to .002% or less before the drug is
permitted to enter the market. "Thus, the degree of risk acceptable in a life-saving drug is
only a tiny fraction of what is acceptable in life-improving surgery." LIFE/DEATH, supra
note 77, at 8-9.
92. Overview, supra note 1, at 413. But see Laetrile: Quacks and Freedom, 1977 BRIT.
MED. J. 3, 3; Culliton, Sloan-Kettering: The Trials of an Apricot Pit-1973, 182 ScI. 1000,
1001 (1973). The manner in which laetrile functions negates the possiblity of cyanide
poisoning. See note 1 supra.
93. Cyanide Poisoning from Ingestion of Apricot Kernels, 24:50 MORBIDITY AND MOR-
TALITY WEEKLY RPT. 427, 427 (1975) (report of symptoms of cyanide poisoning in a 34-year
old man, allegedly caused by consumption of 48 apricot seeds); Overview, supra note 1, at
413 (death of a 17-year old girl and I1-month old girl from swallowing five 500 milligram
laetrile tablets). See also Jukes, Is Laetrile a Vitamin?, 12 NUTRITION TODAY 12, 17 (1977).
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use.9 4 The NCI results removed "the last remaining obstacle to begin-
ning laetrile trials on humans."95 One certified toxicologist stated that
he has "yet to see a single, bona fide, clearly scientific case of amygda-
lin poisoning."96 It should be borne in mind, however, that "'there is
no such thing as a completely safe and effective medicine.' ,97 For ex-
ample, if aspirin were only now to be released, it is doubtful that it
could pass the FDA's standards on toxicity.98 It therefore seems that
the better view is to weigh the side effects and possible risks of a drug
against its benefits, rather than totally prohibiting the drug because of
its possible risks.99 Although laetrile, like the orthodox treatments, has
yet to be proven completely effective, studies conducted with animals
and humans have demonstrated some success. 1°° In addition, some pa-
tients using laetrile experience a relief from pain, improvement in ap-
petite, and a gain in weight. 10' These benefits alone are a refreshing
change for the cancer-ridden patient.
Given the state of the art of cancer therapy, is governmental prohi-
bition of laetrile, which in effect compels the use of orthodox treatment,
really promoting public health?10 2 The answer lies in distinguishing
the non-terminal patient for whom the orthodox treatments may be ef-
94. FDA IndicatesIt Will OKLaetrile Tests on Humans, L.A. Times, Jan. 2, 1980, Part 1,
at 1, col. 1.
95. Id
96. Toxicologist Blasts FDA on Laetrile Toxicity, 5:3 CANCER CONT. J. 138 (1977).
97. LIFE/DEATH, supra note 77, at 9 (quoting Dunlop, The Problem of the Safety of
Drugs in Britain, 23:2 SAETRYKK AV FORMAKOTERAPI at 34 (1967)).
98. Id at 56. Aspirin can cause asthma, hypersensitivity, and even death to some per-
sons after the consumption of a single tablet. Id Also, penicillin, currently a very accepted
drug, could not even be tested on humans under present regulations due to its toxicity. Id
at 53.
99. It is impossible to have effective drugs if they are required to be totally safe. A
physician must judge the use of the drug by its benefits and risks. Id at x.
100. Morrone, Chemotherapy of Inoperable Cancer-Preliminary Report of 10 Cases
Treated with Laetrile, 20 ExP. MED. & SURGERY 299 (1962) (laetrile used on 10 cases of
inoperable cancer resulted in relief of pain, improved appetite, and reduction of ade-
nopathy); Navarro, Laetrile Therapy in Cancer, 4 PHILIPPINE J. OF CANCER 204 (1962) (illus-
trative cases of relief from cancer following large doses of laetrile); Brown & Mortimer,
Remission of Canine Squamous Cell Carcinoma After Nitriloside Therapy, 71 VET. MED. &
SMALL ANIMAL CLINICIAN 1561 (1976) (apparently successful use of laetrile in the treatment
of squamous cell carcinoma in a dog).
101. See note 100 supra.
102. Stated more explicitly:
The real sufferer in all this is the public which has little voice or influence in
these matters. It is always told that it is being protected-but from what? Should
it be guarded. . . from potent drugs. . . that may control or cure its diseases?
Or are the real dangers the degenerative, malignant or parasitical diseases
which, without new drugs, are likely to cripple or kill them?
LIFE/DEATH, supra note 77, at xiv.
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fective from the terminal patient who has exhausted conventional treat-
ments with no success.
The FDA argues that the approval of an unproven drug would
cause patients to delay using possibly effective orthodox treatments. 103
This argument could be valid only with reference to non-terminal pa-
tients. If a patient is afflicted with one of the fifteen types of cancer that
can be controlled, the risks involved in using an unproven treatment
may be greater than the benefits from conventional treatments. There-
fore, under the Wade analysis, there may be a compelling state interest
in protecting the health of the non-terminal patient. If, however, a pa-
tient's condition is terminal and therefore orthodox treatments are of
no avail, the risks in using unproven treatments are appreciably out-
weighed by the possible benefit from the treatment. At the point that a
patient's condition becomes terminal, the "interest of the state in pro-
tecting the individual from an inherently hazardous procedure. . . has
largely disappeared.'
If a terminal patient chooses laetrile with full knowledge that its
effectiveness is unproven, the risks he takes are no greater than are
other self-assumed risks that the state permits. The state allows such
"risk-taking" activities as smoking, drinking alcohol, mountain climb-
ing, driving an automobile without a seatbelt, and riding a motorcycle
without a helmet.1
0 5
The state's interest in the health of its inhabitants is not compelling
when the patient's condition becomes terminal. At early discovery of
the illness, the state may require the use of orthodox treatments; how-
ever, when the condition becomes terminal, the individual's right to use
treatments of unproven efficacy should not be prohibited by the state.
B. Economic Interests
Although not referred to as a compelling state interest, the court in
Privitera stated that there is a legitimate state interest in protecting the
economic savings of individuals and families' 106 Economic interests
103. People v. Privitera, 23 Cal. 3d at 705-06, 591 P.2d at 923-24, 153 Cal. Rptr. at 435-36.
104. Roe v. Wade, 410 U.S. at 149.
105. L. TRIBE, AMERICAN CONSTITUTIONAL LAW 938 (1978). The risks associated with
cigarettes and alcohol are severe. Although the benefits of smoking are small (if any), ciga-
rettes are the cause of 300,000 premature deaths a year, 77 million man-days lost from work,
and an economic cost of 20 billion dollars a year. LIFE/DEATH, supra note 77, at 6. The
social costs of alcohol include automobile accidents, alcoholism, and industrial accidents.
The economic costs are 15 billion dollars a year. Id at 5.
106. 23 Cal. 3d at 705-06, 591 P.2d at 923-24, 153 Cal. Rptr. at 435-36 (citing CAL.
HEALTH & SAFETY CODE § 1700 (West 1979)).
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also have been a major focus of many laetrile opponents. 10 7 The cost of
unproven drugs, however, must be compared to the cost of orthodox
treatments and counterbalanced against the overall economic loss re-
sulting from the regulation of unproven drugs.
Orthodox treatments for the cure of cancer are expensive. It has
been estimated that the median cost for conventional treatment is
$19,000 per patient. 108 Furthermore, the high incidents of fatalities
from orthodox treatments result in an overall morbidity cost to individ-
ual families of 3.5 million dollars per year. 10 9 A second consideration
should be the social-economic loss incurred in regulating unproven
drugs. One study estimated a total loss of 250-350 million dollars per
year from the regulation of unproven drugs.1 0 These figures represent
a severe cost to the public, caused by the stringent requirements of the
FDA regulations.
Government prohibition has also caused the price of laetrile to in-
crease substantially. There is an average mark up of 600% on the cost
of laetrile in the United States over the cost in Mexico."' In Mexico,
the price of tablets ranges from 65 cents to $1.00 and injections range
from $6.00 to $9.00 per 3-gram ampule." 2 A cancer patient is forced to
either pay the expense of traveling to Mexico or purchase laetrile at
inflated prices within the United States. Thus, the fact that laetrile is
illegal throughout most of the United States is the reason for its high
cost to the patient.
The prohibition of laetrile has not protected the economic interests
of patients seeking to use it, nor has the state been successful in guard-
ing against extensive economic loss due to the high cost of orthodox
treatments. A state's interest in protecting patients from economic loss
probably cannot ever be considered a "compelling interest" and cer-
tainly is not sufficient in this instance to justify a state's impingement
upon a patient's right to use laetrile.
107. See Freedom of Choice, supra note 1, at 16; Overview, supra note I, at 413.
108. Overview, supra note 1, at 413.
109. Cromwell, The Cost of Cancer, 89 LARYNGOSCOPE 393, 400 (1979).
110. A study by Sam Peltzman balanced out the risk/benefit ratio of the 1962 drug
amendments in the following economic terms:
Loss of $300,000,000 to $400,000,000 a year in missed benefits from the
reduced flow of useful new drugs.
Gain of about $100,000,000 in money not spent on presumably ineffective
drugs, barred by the new law.
Loss of about $59,000,000 a year because of higher prices paid for drugs, the
result of lessened competition.
LiFE/DEATH, supra note 77, at 103.
111. Laetrile: Quacks and Freedom, 1977 BRIT. MED. J. 1, 3.
112. Dorr, The Current Status ofLaerile, 89 ANNALS OF INTERNAL MED. 389, 390 (1978).
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IV. PROPOSED REGULATION
When a statute regulates a fundamental right, it must be narrowly
drafted to protect only the state's legitimate, compelling interests.' 3 By
tailoring the statute to protect only such state interests, the infringe-
ment upon the right of the individual may be avoided or minimized.
Although there may exist a compelling state interest in the protection of
a non-terminal patient's health, the regulation of drugs of unproven
efficacy can be accomplished by less restrictive means than the present
absolute prohibition.
The state's interest diminishes as the individual's health deterio-
rates, and when the individual's condition becomes terminal, his right
to choose an unproven treatment should not be infringed upon by state
regulation. There is some difficulty, however, in deciding at which
point a patient's condition is "terminal." The Court in United States v.
Ruthe ford"4 recognized that "with diseases such as cancer it is often
impossible to identify a patient as terminally ill except in retrospect.""
5
The Court faced a similar obstacle in Wade when attempting to
define "viability.""' 6 Unlike Rutherford, the Court in Wade overcame
the difficulty in defining this point by recognizing that it is a matter of
medical judgment, skill, and technical ability." 7 Similarly, "terminal'
can be determined adequately on a case-by-case basis by a licensed
physician.""
A state's regulation of laetrile and other treatments of unproven
efficacy can be tailored to protect the state's interest in the non-terminal
patient's health and yet not infringe upon a terminally ill patient's use
of the treatment. The Wade Court achieved a similar result by increas-
ing the state's power to regulate and decreasing the individual's right to
choose an abortion as the pregnancy continues." 9 Analogously, at the
early stages of cancer, the state's interests may be sufficiently compel-
ling to require the use of orthodox treatments, but when the patient's
113. Roe v. Wade, 410 U.S. at 155.
114. 442 U.S. 544 (1979).
115. Id. at 556.
116. Viability is that point of fetal development when the unborn child is able to live
indefinitely outside the womb by natural or artificial life support systems. 410 U.S. at 160.
117. Id at 163; Planned Parenthood v. Danforth, 428 U.S. 52, 61 (1976).
118. The court in Quinlan, when deciding that life support systems may be discontinued
in some instances, applied the term "terminal" and implied that its decision may be applica-
ble to other medical decisions regarding terminal conditions. 70 N.J. at 54, 355 A.2d at 671.
Also the California Natural Death Act requires a determination of when a patient's condi-
tion is "terminal." See notes 43-45 supra.
119. The Court divided a woman's pregnancy into trimesters. At each trimester, the indi-
vidual's rights and the state's interests vary. See note 18 supra.
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condition becomes terminal, the right to choose unproven treatments
should be restricted by only minimal state interference.
An effective alternative to total prohibition was introduced in the
California Senate in 1977. A Senate Bill that would have legalized lae-
trile for all patients was defeated; 2 ' its author, Senator Campbell, had
proposed an amendment whereby terminally ill patients could use lae-
trile. Pursuant to the proposed amendment, if two physicians certified
in writing "that the patient has terminal cancer and that the patient has
requested laetrile and either (a) the patient is currently within a con-
ventional prescribed mode of treatment or (b) conventional treatment
would not be of benefit because of advanced progress of the disease"
12 1
the patient could use laetrile if informed that the drug has not been
proved effective in the treatment of cancer thus far. This alternative
demonstrates that something less than an absolute prohibition can pro-
120. The Senate Bill provided as follows:
SECTION 1. Section 1708.5 is added to the Health and Safety Code, to read:
1708.5. (a) This chapter shall not apply to laetrile or amygdalin or any vita-
mins, minerals, enzymes, or foods for special dietary uses deemed adjunctive or
necessary to laetrile or amygdalin therapy, when prescribed in accordance with the
procedures set forth in subdivision (c) by a physician and surgeon licensed to prac-
tice in the State of California.
(b) The manufacture, sale, prescription, and use of laetrile or amygdalin for
the purposes and in the manner set forth in subdivision (a) shall be lawful within
this state.
(c) A physician and surgeon licensed to practice in the State of California shall
meet each of the following requirements as to any patient before prescribing lae-
trile or amygdalin for such patient:
(1) The patient shall have consented in writing on an informed consent form.
Such informed consent form shall include at least the following:
(A) An explanation of the risks and benefits of laetrile or amygdalin as a form
of cancer therapy.
(B) An explanation of the risks and benefits of standard treatment modalities;
such as chemotherapy, radiation therapy, and surgery, commonly prescribed by
most licensed physicians in California, a substantial part of whose practices include
treatment for cancer.
(C) A statement explaining to the patient that such patient can withdraw from
the laetrile or amygdalin therapy at any time during the course of treatment.
(D) A statement explaining that laetrile or amygdalin need not be used to the
exclusion of the standard treatment modalities.
(E) A statement which encourages the patient to consult with a second physi-
cian who specializes in the use of standard treatment modalities for cancer prior to
using laetrile or amygdalin.
(2) The informed consent form shall be signed and dated by both the physi-
cian and patient and shall be retained in the patient's medical record.
(d) In enacting this section, the Legislature finds and declares that the efficacy
of the use of laetrile or amygdalin with respect to cancer therapy has not been
determined.
SB 245, Cal. Legis. Serv. (West 1977-78).
121. Assembly Committee on Health-Legislative Hearing on SB 245 (Campbell) Relaling
to Laetrile 127-28, Aug. 8, 1977. Presently, a similar bill is under consideration in the Cali-
fornia Legislature.
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tect the state's interests and yet preserve the fundamental right of the
terminally ill to choose unproven treatments.
V. CONCLUSION
The constitutional protection afforded to an individual's right de-
pends upon the nature of the right involved. In accordance with the
Griswold and Wade standard, the right to choose an unproven treat-
ment is a decision that is basic to the life of the individual and therefore
it should be constitutionally protected as a fundamental right. Only a
compelling state interest may justify a statute that infringes upon this
right. The state interest is insufficient to bar a terminally ill patient's
right to choose alternative treatments. By narrowly drafting the statute
so that its regulations on the use of an unproven treatment vary in ac-
cordance with the stages of illness, the state interest in the public health
of its inhabitants can be protected without impinging upon the funda-
mental right of the terminally ill patient to choose any treatment that
may preserve his life.
V Anthony Unan
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